Sarah L George1, Mimi A Wong2, Tina J T Dube2, Karen L Boroughs3, Janae L Stovall3, Betty E Luy3, Aurelia A Haller3, Jorge E Osorio4, Linda M Eggemeyer5, Sharon Irby-Moore5, Sharon E Frey5, Claire Y-H Huang3, Dan T Stinchcomb4. 1. Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine St. Louis Veterans Administration Medical Center, Missouri. 2. EMMES Corporation, Rockville, Maryland. 3. Arboviral Diseases Branch, Division of Vector-Borne Disease, Centers for Disease Control and Prevention, Fort Collins, Colorado. 4. Takeda Vaccines, Deerfield, Illinois. 5. Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine.
Abstract
BACKGROUND: Dengue viruses (DENVs) infect >300 million people annually, causing 96 million cases of dengue disease and 22 000 deaths [1]. A safe vaccine that protects against DENV disease is a global health priority [2]. METHODS: We enrolled 72 flavivirus-naive healthy adults in a phase 1 double-blinded, randomized, placebo-controlled dose-escalation trial (low and high dose) of a live attenuated recombinant tetravalent dengue vaccine candidate (TDV) given in 2 doses 90 days apart. Volunteers were followed for safety, vaccine component viremia, and development of neutralizing antibodies to the 4 DENV serotypes. RESULTS: The majority of adverse events were mild, with no vaccine-related serious adverse events. Vaccinees reported injection site pain (52% vs 17%) and erythema (73% vs 25%) more frequently than placebo recipients. Low levels of TDV-serotype 2 (TDV-2), TDV-3, andTDV-4 viremia were observed after the first but not second administration of vaccine. Overall seroconversion rates and geometric mean neutralization titers after 2 doses were 84.2% and 54.1, respectively, for DENV serotype 1 (DENV-1); 92.1% and 292.8, respectively, for DENV-2; 86.8% and 32.3, respectively, for DENV-3; and 71.1% and 15.0, respectively, for DENV-4. More than 90.0% of high-dose recipients had trivalent or broader responses. CONCLUSIONS:TDV was generally well tolerated, induced trivalent or broader neutralizing antibodies to DENV in most flavivirus-naive vaccinees, and is undergoing further development. CLINICAL TRIALS REGISTRATION: NCT01110551.
RCT Entities:
BACKGROUND:Dengue viruses (DENVs) infect >300 million people annually, causing 96 million cases of dengue disease and 22 000 deaths [1]. A safe vaccine that protects against DENV disease is a global health priority [2]. METHODS: We enrolled 72 flavivirus-naive healthy adults in a phase 1 double-blinded, randomized, placebo-controlled dose-escalation trial (low and high dose) of a live attenuated recombinant tetravalent dengue vaccine candidate (TDV) given in 2 doses 90 days apart. Volunteers were followed for safety, vaccine component viremia, and development of neutralizing antibodies to the 4 DENV serotypes. RESULTS: The majority of adverse events were mild, with no vaccine-related serious adverse events. Vaccinees reported injection site pain (52% vs 17%) and erythema (73% vs 25%) more frequently than placebo recipients. Low levels of TDV-serotype 2 (TDV-2), TDV-3, and TDV-4 viremia were observed after the first but not second administration of vaccine. Overall seroconversion rates and geometric mean neutralization titers after 2 doses were 84.2% and 54.1, respectively, for DENV serotype 1 (DENV-1); 92.1% and 292.8, respectively, for DENV-2; 86.8% and 32.3, respectively, for DENV-3; and 71.1% and 15.0, respectively, for DENV-4. More than 90.0% of high-dose recipients had trivalent or broader responses. CONCLUSIONS: TDV was generally well tolerated, induced trivalent or broader neutralizing antibodies to DENV in most flavivirus-naive vaccinees, and is undergoing further development. CLINICAL TRIALS REGISTRATION: NCT01110551.
Authors: C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney Journal: J Virol Date: 2000-04 Impact factor: 5.103
Authors: Aaron C Brault; Richard M Kinney; Payal D Maharaj; Emily N G Green; William K Reisen; Claire Y-H Huang Journal: Vector Borne Zoonotic Dis Date: 2011-02-01 Impact factor: 2.133
Authors: Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman Journal: Hum Vaccin Date: 2009-01-27
Authors: Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb Journal: Am J Trop Med Hyg Date: 2011-06 Impact factor: 2.345
Authors: Robert V Gibbons; Siripen Kalanarooj; Richard G Jarman; Ananda Nisalak; David W Vaughn; Timothy P Endy; Mammen P Mammen; Anon Srikiatkhachorn Journal: Am J Trop Med Hyg Date: 2007-11 Impact factor: 2.345
Authors: Whitney R Baldwin; Jill A Livengood; Holli A Giebler; Janae L Stovall; Karen L Boroughs; Stephanie Sonnberg; Kelly J Bohning; Elizabeth A Dietrich; Yee Tsuey Ong; Hoang K Danh; Hetal K Patel; Claire Y-H Huang; Hansi J Dean Journal: Sci Rep Date: 2018-11-07 Impact factor: 4.379
Authors: Justina O Tam; Helena de Puig; Chun-Wan Yen; Irene Bosch; Jose Gómez-Márquez; Charles Clavet; Kimberly Hamad-Schifferli; Lee Gehrke Journal: J Immunoassay Immunochem Date: 2016-12-16
Authors: Haiyan Chu; Sarah L George; Dan T Stinchcomb; Jorge E Osorio; Charalambos D Partidos Journal: J Infect Dis Date: 2015-05-05 Impact factor: 5.226
Authors: Jesica A Swanstrom; Sandra Henein; Jessica A Plante; Boyd L Yount; Douglas G Widman; Emily N Gallichotte; Hansi J Dean; Jorge E Osorio; Charalambos D Partidos; Aravinda M de Silva; Ralph S Baric Journal: J Infect Dis Date: 2018-05-25 Impact factor: 5.226